Pricing Log in Create free account
Friday 6 November 2026 Export PCRX’s income statement to Excel — free account

Pacira BioSciences, Inc.

PCRX Healthcare Drug Manufacturers Specialty & Generic

Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024.

Revenue
−1.59%
EPS
+500.0%
Free cash flow
−18.5%
Total debt
−37.4%

Quarter to September 2026, against a year earlier

36.44 0.04 +0.11%
Market cap
$1.5B
P/E
38.4×
Fwd P/E
56.6×
Dividend yield
—
F-score
8/9
Altman Z
2.02
Beneish M
−2.93
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 2.39
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 1 1 2 2 2 — 2 — 1 — 1 —
Insider Ownership 3.75%

Capital & Financial Ratios $m

Size
Market Cap 1,450.00
Revenue ttm 743.30
Net income ttm 37.73
Free cash flow ttm 169.00
Net debt Q (295.58)
Valuation
P/E 38.36 (above 35: high)
Forward P/E 56.60 (above 35: high)
Price / sales 1.95
Forward P/S Powerpack
Price / FCF 8.60
Price / book 2.04
Financial health
Current ratio Q 4.68 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q 7.72
Growth
Revenue growth Q −1.59% (below 0%: shrinking)
Operating income growth Q +250.08% (above 0%: growing)
EPS, this year +9.28%
EPS, next year A +19.44% (at or above 15%: strong)
Revenue, next year A +3.84%
EPS, past 5 yrs −45.51% (below 0%: weak)
EPS, next 5 yrs A +20.25% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.3×, against a ten-year median of 4.3×; over the ten years it ranged from 1.2× in 2024 to 8.1× in 2016.
P/E against its own 10 years 34.75%
10-year low 10-year high
P/S against its own 10 years 23.80%
10-year low 10-year high
P/B against its own 10 years 29.37%
10-year low 10-year high
EV/Sales against its own 10 years 23.65%
10-year low 10-year high
EV/FCF against its own 10 years 22.50%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 279 485 238 296
Receivables 106 113 124 123
Inventory 104 125 153 129
Other — — — —
510 745 548 590
2023 2024 2025 Q'26
Payables 16 19 15 18
ST’ Debt 9 202 — —
Other — — — —
97 310 121 126

Compound Annual Growth %

10y 5y 3y
Sales 11.30% 11.07% 2.89%
Cash Flow 18.42% 14.56% 1.52%
Earnings 14.25% (45.44%) (23.82%)
Book Value 12.24% 2.26% (3.65%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.64 Actual 0.73

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.65 0.70 Beat by 0.05
Q4 FY25 0.85 0.57 Miss by 0.28
Q1 FY26 0.61 0.60 Miss by 0.01
Q2 FY26 0.64 0.73 Beat by 0.09
Q3 FY26 0.76 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 0.07 0.12 0.70 — —
’25 0.10 (0.11) 0.12 0.04 0.16
’24 0.19 0.39 (3.11) 0.34 (2.15)
’23 (0.43) 0.51 0.23 0.50 0.89
’22 0.15 0.40 (0.02) (0.22) 0.34
’21 0.23 0.42 0.39 (0.12) 0.92
’20 0.19 (0.17) 2.94 0.32 3.33
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 177 192 177 — —
’25 169 181 180 197 726
’24 167 178 169 187 701
’23 160 169 164 181 675
’22 158 169 167 172 667
’21 119 136 128 159 542
’20 106 76 117 131 430
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 26 57 50 — —
’25 35 12 61 44 152
’24 49 53 54 33 189
’23 19 43 44 48 155
’22 31 30 43 42 145
’21 12 30 60 23 126
’20 6 (16) 40 47 77
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 23 56 46 — —
’25 27 9 57 43 137
’24 46 52 50 31 179
’23 13 40 41 46 139
’22 23 18 37 37 115
’21 (1) 20 47 14 80
’20 (1) (25) 32 32 39
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 276 287 337 421 430 542 667 675 701 726 743 +11.3% 754 790 883 +6.7%
Gross margin, % 60.16 69.33 74.25 74.65 72.69 74.10 70.11 72.64 75.69 79.39 0.00 +19.2 pt
EBT (38) (42) 0 (11) 20 56 13 62 (63) 17 37 n/m
EBT margin, % (13.69) (14.82) (0.13) (2.55) 4.68 10.42 1.99 9.14 (9.00) 2.32 4.97 +16.0 pt
Net income (38) (43) 0 (11) 146 42 16 42 (100) 7 38 n/m
Per share, $
Per share, $ Revenue 7.42 7.20 8.24 10.14 10.07 12.23 14.65 14.60 15.16 16.30 18.65 +9.1%
Earnings (1.02) (1.07) (0.01) (0.27) 3.41 0.95 0.35 0.91 (2.15) 0.16 0.95 n/m
Cash flow 0.90 0.45 1.19 1.70 1.81 2.84 3.19 3.35 4.10 3.41 4.44 +16.0%
Capex (0.66) (0.48) (0.35) (0.24) (0.89) (1.04) (0.66) (0.33) (0.23) (0.34) (0.20) (7.0%)
Free cash flow 0.23 (0.04) 0.84 1.45 0.92 1.80 2.53 3.02 3.87 3.07 4.24 +33.0%
Book value 5.88 7.02 7.85 8.55 14.52 16.50 17.03 18.83 16.83 15.55 17.87 +11.4%
Shares, m 37 40 41 42 43 44 46 46 46 45 41 +2.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 17.70 63.34 109.50 35.56 0.00 172.53 38.36 39.9
P/S 4.68 6.43 5.22 4.47 5.94 4.92 2.65 2.19 1.24 1.59 1.95 3.9
P/B 5.91 6.59 5.48 5.30 4.12 3.65 2.28 1.70 1.12 1.66 2.04 3.8
EV/Sales 4.45 6.31 4.94 4.51 5.82 5.00 3.25 2.55 1.39 2.05 2.32 4.0
EV/FCF 140.68 (1,220.69) 48.53 31.47 63.77 33.88 18.84 12.35 5.44 10.90 10.19 (85.5)
Cash, $m
Cash, $m Operating cash flow 33 18 49 71 77 126 145 155 189 152 177 +18.3%
Capex (25) (19) (15) (10) (38) (46) (30) (15) (11) (15) (8) (5.2%)
Free cash flow 9 (1) 34 60 39 80 115 139 179 137 169 +35.7%
Balance, $m
Balance, $m Working capital 198 335 417 301 398 345 351 413 435 427 464 +8.9%
Net debt (64) (35) (93) 19 (52) 42 401 244 101 134 (296) n/m
Shareholders’ equity 219 279 321 355 620 730 775 870 778 693 712 +13.7%
Returns, %
Returns, % ROA (9.74) (8.36) (0.07) (1.45) 13.82 2.51 0.85 2.58 (6.37) 0.50 3.02 +10.2 pt
ROIC (12.90) (6.38) 4.36 1.75 5.10 7.27 3.19 4.92 (5.22) 1.45 5.37 +14.4 pt
ROE (17.35) (17.10) (0.16) (3.26) 29.86 6.22 2.11 5.10 (12.08) 0.96 5.24 +18.3 pt
People
People Employees 503 489 518 606 624 697 715 712 790 829 — +5.7%
Revenue/emp, $m 0.55 0.59 0.65 0.69 0.69 0.78 0.93 0.95 0.89 0.88 — +5.3%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Sep 2026 · fundamentals updated 5 Nov 2026

Pacira BioSciences, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
XERS Xeris Biopharma Holdings, Inc. $2.4B — (loss-making) — (loss-making) +44.16% (above 0%: growing) +1,478.95% (above 0%: growing) +93.18% (above 0%: growing) 88.41% 15.78% Compare
ALVO Alvotech $1.8B — (loss-making) 111× +2,310.95% (above 0%: growing) −99.51% (below 0%: shrinking) −496.58% (below 0%: shrinking) 56.47% 9.14% Compare
ANIP ANI Pharmaceuticals, Inc. $1.6B 13.3× 14.3× +27.64% (above 0%: growing) +29.41% (above 0%: growing) +85.49% (above 0%: growing) 61.64% 18.01% Compare
PCRX Pacira BioSciences, Inc. $1.5B 38.4× 56.6× −1.59% (below 0%: shrinking) +500.00% (above 0%: growing) −18.47% (below 0%: shrinking) 0.00% 12.61%
PAHC Phibro Animal Health Corporation $1.4B 14.0× 12.6× +6.29% (above 0%: growing) +12.31% (above 0%: growing) +262.08% (above 0%: growing) 33.23% 12.83% Compare
CRON Cronos Group Inc. $1.4B 21.9× 19.5× +74.61% (above 0%: growing) −42.86% (below 0%: shrinking) +179.64% (above 0%: growing) 50.88% 14.23% Compare
ETON Eton Pharmaceuticals, Inc. $1.4B 26.8× 48.0× +157.91% (above 0%: growing) n/m +172.55% (above 0%: growing) 76.48% 39.73% Compare
AMPH Amphastar Pharmaceuticals, Inc. $1.2B 12.3× 12.8× +8.22% (above 0%: growing) +134.21% (above 0%: growing) −29.38% (below 0%: shrinking) 47.99% 24.46% Compare
HROW Harrow, Inc. $976.2M — (loss-making) — (loss-making) +10.85% (above 0%: growing) n/m −838.78% (below 0%: shrinking) 71.27% (15.58%) Compare
Median of peers $1.4B 14.0× 16.9× +35.90% +20.86% +89.34% 59.05% 15.01%

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 29 April 2025

Ownership

Directors and executive officers, together 6.40%
BlackRock, Inc. 17.50%
The Vanguard Group 11.00%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Pacira BioSciences, Inc. (PCRX) Latest News

5 Nov

Impact 4 · · Moby
Impact 4 · · PR Newswire

30 Oct

Impact 5 · · PR Newswire

29 Oct

Impact 4 · · Zacks

27 Oct

Impact 4 · · Stocktwits

23 Oct

Impact 4 · · Simply Wall St.

9 Oct

Impact 4 · · Zacks
Impact 4 · · Simply Wall St.
Impact 3 · · MT Newswires

8 Oct

Impact 5 · · qz.com
Impact 5 · · PR Newswire
Impact 4 · · Simply Wall St.
Impact 4 · · pharmaceutical-technology.com
Impact 4 · · MT Newswires
Impact 4 · · biopharmadive.com
Impact 4 · · The Motley Fool
Impact 4 · · InvestorsHub

7 Oct

Impact 3 · · GlobeNewswire

6 Oct

Impact 4 · · Simply Wall St.
Impact 4 · · Zacks
Impact 4 · · pharmaceutical-technology.com

5 Oct

Impact 4 · · GlobeNewswire

12 Aug

Impact 3 · · The Motley Fool transcript

10 Aug

Impact 4 ·

6 Aug

Impact 3 ·
Impact 3 ·

5 Aug

Impact 3 ·
Impact 3 · · Moby transcript
Impact 3 · transcript

4 Aug

Impact 3 · · MarketBeat
stockrow.com/PCRX · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com